Core Insights - The article highlights the significant progress made in controlling viral hepatitis in China, particularly in reducing new infections and achieving the goal of eliminating mother-to-child transmission of hepatitis B [1][2]. Group 1: Current Status of Hepatitis in China - Approximately 75 million individuals in China are infected with the hepatitis B virus, with new infections effectively controlled [1]. - The prevalence of hepatitis B surface antigen among the population has been steadily declining, with the mother-to-child transmission rate in nine provinces falling below 1%, meeting WHO standards [2][4]. Group 2: Vaccination and Treatment Measures - Vaccination rates for hepatitis A and B among newborns remain high, with the hepatitis B surface antigen positivity rate among children under five dropping to 0.3%, achieving WHO's regional control targets [4]. - The inclusion of antiviral drugs in medical insurance and essential drug lists, along with centralized procurement, has significantly reduced drug prices and alleviated the financial burden on patients [4]. Group 3: Clinical Cure and Management - Over 1,000 hospitals in China have established clinics for the clinical cure of hepatitis B, promoting the concept of achieving clinical cure through the elimination of hepatitis B surface antigen [7][9]. - Research indicates that chronic hepatitis B patients have a liver cancer risk 15 to 20 times higher than the general population, but achieving clinical cure can reduce this risk to that of healthy individuals [6][7]. Group 4: Future Goals and Challenges - The Chinese health authorities aim to intensify efforts in diagnosis, discovery, and treatment to meet the WHO's goal of eliminating viral hepatitis as a public health threat by 2030 [4].